ALL Hub provides robust coverage for American Society of Hematology (ASH) Annual Meeting and Exposition

Press release: Available for immediate release

The ALL Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in acute lymphoblastic leukemia (ALL). The ALL hub has continued to promote significant developments in the treatment and research of ALL throughout Quarter 4 of 2021.

In October, the ALL Hub provided highlights from the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021). We updated our audience on the optimization and role of transplantation and cellular therapies in the field of hematologic malignancies.

In Q4, the ALL Hub held a virtual meeting with the members of our prestigious Steering Committee, focused on determining more robust and valuable scientific content that will be added to the ALL Hub in the next months.

In the coming weeks, the ALL Hub will be covering the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, utilizing a hybrid model of both in-person and virtual participation in order to deliver the best possible content. To help navigate the exciting research being presented, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

The ALL Hub published a series of educational theme articles, summarizing different genetic subtypes of B-ALL and discussing the impact of these subtypes on current risk criteria and treatment responses.

Reviewing the ALL Hub’s impact this quarter, Mia Hill, IME Director at Scientific Education Support, said:

“We are delighted with the progress made by the ALL Hub during this quarter. The website sessions have continued to grow since the launch of the hub in April this year and October was the most successful month to date with over 3000 page views. We are seeing a strong end to the year, which should set up the hub for a promising finish to 2021. Reporting at such prestigious congresses enables us to share the opinions of experts in the field, covering cutting-edge research, new treatments, and diagnostic strategies.”

We are extremely grateful to all our supporters - Amgen, Novartis, and Pfizer whose financial support has helped us achieve this success throughout 2021.


For more information on the ALL Hub, please visit

For media enquiries or to explore collaboration opportunities, please contact or


About acute lymphoblastic leukemia (ALL)

ALL is a rare form of blood cancer characterized by uncontrolled proliferation of immature stem cells of lymphoid lineage. It is the most common form of leukemia in children, and the second most common acute leukemia in adults.

ALL is associated with various chromosomal and genetic abnormalities, which has led to the development of risk stratification and promising new targeted agents. However, while treatment outcomes are favorable in childhood ALL, in older patients, poor prognosis and treatment tolerability are still a major concern.

About the ALL Hub

The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on ALL. Our aim is to enhance knowledge of ALL through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The ALL Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the ALL Hub supports HCPs worldwide.

Founded in partnership with the European School of Haematology (ESH) in 2021, the ALL Hub is guided by an international steering committee of experts in the field of ALL. The steering committee meet regularly to discuss the performance of the ALL Hub and to devise action plans on how best to support the ALL community and address any unmet educational needs.

ALL Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

  • Amgen
  • Novartis
  • Pfizer

If you are interested in becoming an ALL Hub supporter, please contact

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, Multiple Myeloma Hub, and MPN Hub.

About the European School of Haematology (ESH)

The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in haematology.

Press release distributed by Pressat on behalf of Scientific Education Support, on Wednesday 15 December, 2021. For more information subscribe and follow

Health Medical & Pharmaceutical
Published By

Scientific Education Support
Visit Newsroom


No media attached. Please contact Scientific Education Support for more information.

Additional PR Formats

You just read:

ALL Hub provides robust coverage for American Society of Hematology (ASH) Annual Meeting and Exposition